Store
COVID-19 Testing Markets, 2023
Publication Date: May 18, 2023
Tags: COVID-19, Infectious Diseases, Pharmaceuticals, Vaccines
Pages: 130
SKU: 23-045
As the COVID-19 pandemic evolves into an endemic phase, the landscape of COVID-19 testing is changing rapidly. Kalorama Information’s COVID-19 Testing Markets, 2023 report provides crucial insights into this shifting market, answering key questions and providing valuable market sizing and estimates.
Key Insights Provided:
- Market impacts and trends in the evolving COVID-19 testing market
- Importance of testing and its role in pandemic response
- Development of a wide selection of diagnostic tests across all markets
- Market sizing and estimates for COVID-19 tests
Key Topics and Trends Explored:
- At-Home Testing
- Insurance Coverage
- Multiplex Testing
- Expiration of Public Health Emergency
- New Variants on the Horizon
- Immunoassay Testing
- Molecular Testing
- Global Regional Analysis
Global Analysis and Regional Breakdown:
The report offers detailed sales estimates and forecasts for the period 2022-2027, covering regions and countries including APAC, Europe, North America, and Rest of World. Specific countries covered include Australia, Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, India, Italy, Mexico, Netherlands, Japan, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, and United States.
Competitive Analysis:
The report includes analysis and profiles of key companies competing in the COVID-19 testing market, with a focus on the top competitors based on 2022 manufacturer revenues.
Market Data and Forecasting:
All market data pertains to the world market at the manufacturers’ level, with data provided for 2022 and 2027, along with compound annual growth rates (CAGRs). Regional breakdowns are surveyed for North America, Europe, Asia-Pacific, and Rest of World. The forecasted market analysis through 2027 is based on demographic trends, new developments, trajectory of COVID-19 and its variants, innovative technology, and global use.
Table: Global Rapid-based COVID-19 Testing Market, Distribution of Sales, by Segment, 2022-2027 ($MN)
| Segment | Sales 2022 | % Mkt | Sales 2027 | % Mkt |
| Immunoassay | $XX Million | XX% | $XX Million | XX% |
| Molecular | $XX Million | XX% | $XX Million | XX% |
| Total, Rapid-based COVID-19 Market | $XX Million | XX% | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
Industry at a Glance
Scope and Methodology
Size and Growth of the Market
- Table 1-1: Global COVID-19 Testing (Immunoassay, Molecular, Rapid) Sales by Segment, 2022-2027
- Figure 1-1: Global COVID-19 Market by Key Segment (Molecular, Immunoassay), 2020-2027
Key Issues and Trends Affecting the Market
Competitive Outlook
Conclusion Highlights
Chapter 2: Introduction
Overview
- Figure 2-1: Coronavirus (COVID-19) 7-Day Case Snapshot Global by Country
- Table 2-1: Coronavirus (COVID-19) Situation by WHO Region (Africa, Americas, Eastern Mediterranean, Europe, South-East Asia, West Pacific)
- Figure 2-2: Coronavirus (COVID-19) Cumulative Cases and 7-Day Cases by WHO Region (Africa, Americas, Eastern Mediterranean, Europe, South-East Asia, West Pacific)
- Figure 2-3: Country-Level COVID-19 Cumulative Cases, by Country (Australia, Brazil, Canada, France, Germany, India, Indonesia, Italy, Japan, Mexico, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom, United States, Vietnam), Through April 11, 2023
- Figure 2-4: Country-Level COVID-19 Cumulative Diagnostic Tests Administered, by Country (Australia, Brazil, Canada, France, Germany, India, Indonesia, Italy, Japan, Mexico, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom, United States, Vietnam), Through April 11, 2023
- Figure 2-5: New Cases vs. Total Cases for Select Countries with Uptick in Cases, by Country (Afghanistan, Austria, Czechia, Hong Kong, Indonesia, Japan, Mexico, Pakistan, Philippines, Poland, Russia, Saudi Arabia, South Korea, Vietnam), April 2023
Chapter 3: Issues and Trends
At-Home Testing
- Figure 3-1: At-Home COVID-19 Test Distribution of Sales, by Vendor (Abbott Diagnostics, Becton Dickinson, OraSure Technologies, Quidel, Siemens Healthineers, Others)
Insurance Coverage
Multiplex Testing
EUAs and Public Health Emergency Expiration
New Variants On the Horizon
Chapter 4: COVID-19 Immunoassay Testing
Overview
Enzyme-linked Immunosorbent Assay (ELISA)
Mass Spectrometry
Rapid
Products
Antigen
- Table 4-1: Selected Antigen Immunoassay Tests for SARS-CoV-2
Antibody
- Table 4-2: Selected Antibody Immunoassay EUA Tests for COVID-19
Market Size and Growth
- Table 4-3: Global Immunoassay COVID-19 Testing Market, 2022-2027 $MN; CAGR 2022-2027
- Table 4-4: Estimated Global Immunoassay COVID-19 Testing Market Distribution by Segment (Antigen, Serology) and End User (Laboratory, Rapid/Near Patient), 2022, (%)
Competitive Market Share
- Figure 4-1: Immunoassay COVID-19 Vendor Market Share, by Vendor (Abbott, Beckman Coulter-Danaher, Becton Dickson, Diasorin, Fujirebio Diagnostics, PerkinElmer, QuidelOrtho, Roche, Siemens, ThermoFisher, Others), 2022 (%)
Chapter 5: COVID-19 Molecular Testing
Overview
Products
- Table 5-1: Selected Molecular EUA Tests for COVID-19
Market Size and Growth
- Table 5-2: Estimated Global Molecular COVID-19 Testing Market, 2022-2027 $MN; CAGR 2022-2027
- Table 5-3: Estimated Global Molecular COVID-19 Testing Market Distribution by End User (Laboratory, Rapid/Near Patient), 2022 (%)
Competitive Market Share
- Figure 5-1: Molecular COVID-19 Vendor Market Share, by Vendor (Abbott, bioMérieux, Cepheid-Danaher, Hologic, Orasure Technologies, PerkinElmer, Qiagen, QuidelOrtho, Roche, ThermoFisher, Others), 2022 (%)
Chapter 6: Total COVID-19 Testing Market Summary
Market Overview
- Table 6-1: Global COVID-19 Testing (Immunoassay, Molecular, Rapid) Sales, by Segment, 2022-2027 ($MN)
- Figure 6-1: Global IVD Market (COVID-19 Assays and Instruments, Excluding COVID-19 Assays and Instruments), 2019-2022, ($MN)
- Figure 6-2: Global IVD Market, Distribution by Performance Segment (COVID-19 Assays and Instruments, Excluding COVID-19 Assays and Instruments), 2022 (%)
Market Segment by Test Type/Site
- Table 6-2: Global COVID-19 Testing by Test Site (Laboratory, Rapid/Near Patient) Sales by Segment, 2022-2027
- Figure 6-3: Global COVID-19 IVD Market by Test Site, 2020-2022 and Forecast Through 2027 ($MN)
Laboratory Based
- Table 6-3: Global Lab-based COVID-19 Testing Market, Distribution of Sales by Segment (Immunoassay, Molecular), 2022-2027 ($MN)
Point of Care
- Table 6-4: Global Rapid-based COVID-19 Testing Market, Distribution of Sales by Segment (Immunoassay, Molecular), 2022-2027 ($MN)
- Figure 6-4: Global COVID-19 IVD Market by Test Method, 2020-2022 and Forecast Through 2027 ($MN)
Market by Region
- Figure 6-5: Estimated Global COVID-19 Testing Market by Region (APAC, Europe, North America, Rest of World), 2020-2022
- Figure 6-6: COVID-19 Testing Market by Country (Australia, Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, India, Italy, Mexico, Netherlands, Japan, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States), Estimated 2022 ($M)
Competitive Analysis
- Figure 6-7: Top 10 COVID-19 Vendors and Global Market Share, by Vendor (Abbott, bioMérieux, Danaher, Hologic, PerkinElmer, Qiagen, QuidelOrtho, Roche, Siemens, ThermoFisher, Others), 2022
Chapter 7: Selected Market Participants
Abbott
- Table 7-1: Abbott Corporate Summary
Company Overview
COVID-19
Access Bio, Inc
- Table 7-2: Access Bio Corporate Summary
Company Overview
COVID-19
Becton-Dickinson
- Table 7-3: Becton-Dickinson Corporate Summary
Company Overview
COVID-19
bioMérieux
- Table 7-4: bioMérieux Corporate Summary
Company Overview
COVID-19
Bio-Rad
- Table 7-5: Corporate Summary
Company Overview
COVID-19
Cue Health
- Table 7-6: Cue Health Corporate Summary
Company Overview
COVID-19
Danaher Corporation
- Table 7-7: Danaher Corporate Summary
Company Overview
COVID-19
DiaSorin S.p.A.
- Table 7-8: DiaSorin Corporate Summary
Company Overview
COVID-19
ELITech Group S.A.S.
- Table 7-9: ELITech Group Corporate Summary
Company Overview
COVID-19
Genedrive plc
- Table 7-10: Genedrive Corporate Summary
Company Overview
COVID-19
Hologic, Inc
- Table 7-11: Hologic Corporate Summary
Company Overview
COVID-19
LumiraDx UK Limited
- Table 7-12: LumiraDx Corporate Summary
Company Overview
COVID-19
OraSure Technologies, Inc.
- Table 7-13: OraSure Technologies Summary
Company Overview
COVID-19
PerkinElmer, Inc
- Table 7-14: PerkinElmer Corporate Summary
Company Overview
COVID-19
QIAGEN N.V.
- Table 7-15: QIAGEN Corporate Summary
Company Overview
COVID-19
QuantuMDx Group, Ltd.
- Table 7-16: QuantuMDx Corporate Summary
Company Overview
COVID-19
QuidelOrtho Corporation
- Table 7-17: QuidelOrtho Corporate Summary
Company Overview
COVID-19
Roche Diagnostic Corporation
- Table 7-18: Roche Diagnostic Corporate Summary
Company Overview
COVID-19
Seegene, Inc
- Table 7-19: Seegene Corporate Summary
Company Overview
COVID-19
Siemens Healthineers GmbH
- Table 7-20: Siemens Healthineers Corporate Summary
Company Overview
COVID-19
Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co)
- Table 7-21: Snibe Corporate Summary
Company Overview
COVID-19
ThermoFisher Scientific
- Table 7-22: Thermo Fisher Scientific Corporate Summary
Company Overview
COVID-19
Related products
Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028
November 29, 2023
In recent decades, genetic technologies for research and diagnostics have transformed healthcare, offering new possibilities in precision medicine and disease management. Next-generation sequencing (NGS) has revolutionized genetic disease diagnostics and oncology, providing comprehensive insights at a relatively low cost. PCR continues to evolve, remaining a central tool in molecular diagnostics. In situ hybridization techniques (ISH)…
Price range: $5,000.00 through $7,500.00
In Vitro Diagnostic (IVD) Trends and Market Update: March 2024
March 26, 2024
Explore the latest trends and developments in the in vitro diagnostic (IVD) market with Kalorama Information’s comprehensive report, In Vitro Diagnostic (IVD) Trends and Market Update: March 2024. Gain insights into key growth segments, industry trends, and emerging technologies shaping the future of IVD.
The report offers updated data analysis based on Kalorama Information’s annual…
Price range: $5,000.00 through $7,875.00
The IVD Market in South Korea, 2024
February 26, 2024
Gain valuable insights into South Korea’s in vitro diagnostics (IVD) market with Kalorama Information’s comprehensive report, The IVD Market in South Korea, 2024. We offer a detailed analysis of South Korea’s IVD revenues for 2023 and forecasts for 2028, segmented into key categories such as clinical chemistry, immunoassay, microbiology/molecular testing, point-of-care (POC),…
Price range: $5,000.00 through $7,875.00
